-

Mauna Kea Technologies Announces its 2022 Financial Calendar

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of its 2022 Financial Calendar.

Event

Date*

2021 Full-Year Financial Results and 2022 First-Quarter Sales

April 21, 2022

2022 Second-Quarter and First-Half Sales

July 21, 2022

2022 First-Half Financial Results

September 22, 2022

2022 Third-Quarter Sales

October 27, 2022

* Subject to modification. Press releases are published after market closes.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com

Disclaimer

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties, including the risks set in the Universal Registration Document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 17, 2021 under number D-21-0566 and the amendment to the 2020 Universal Registration Document filed with the AMF on September 17, 2021, which are both available on the Company's website (www.maunakeatech.com), and risks relating the economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.

Contacts

NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Mauna Kea Technologies

BOURSE:MKEA

Release Versions

Contacts

NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

More News From Mauna Kea Technologies

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth Paris ISIN code: FR0010609263, Ticker: ALMKT Website: www.maunakeatech.com Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) November 30, 2025 177,445,151 178,544,110 178,544,110 (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Arti...

Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management

LOS ANGELES & PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform and TaeWoong Medical USA, a leader in minimally invasive gastrointestinal (GI) diagnostic and therapeutic EUS guided solutions, today announced the signing of an exclusive partnership in the United States to bring physicians and hospitals the industry’s first fully int...

Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that it has obtained approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of its next-generation Cellvizio (Gen 3) platform. This registration was processed and obtained directly by Mauna Kea Technologies S....
Back to Newsroom